Results 21 to 30 of about 3,196 (199)

Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase II randomized placebo-controlled trial. [PDF]

open access: yesDev Med Child Neurol
Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16157 In this double‐blind, placebo‐controlled, randomized clinical trial, 31 adolescents with neurofibromatosis type 1 (NF1) were enrolled to test the effects of lamotrigine on cognitive functioning.
Ottenhoff MJ   +13 more
europepmc   +2 more sources

Spécificité de la transformation sarcomateuse de la maladie de Recklinghausen: à propos de deux cas et revue de la littérature

open access: yesThe Pan African Medical Journal, 2013
5 à 10% des patients atteints de neurofibromatose de type 1 (NF1) développent des tumeurs malignes des gaines des nerfs périphériques (Malignant peripheral nerve sheath tumor : MPNST) contre 0,001% dans la population générale. A travers deux observations
Mouna Bourhafour   +5 more
doaj   +1 more source

Avaliação da motricidade orofacial em indivíduos com neurofibromatose tipo 1

open access: yesRevista CEFAC, 2015
OBJETIVO: descrever e caracterizar as alterações da motricidade orofacial de indivíduos com neurofibromatose tipo 1 (NF1) e correlacionar as alterações encontradas com manifestações clínicas da neurofibromatose tipo 1, mais especificamente com a redução ...
Carla Menezes da Silva   +2 more
doaj   +1 more source

Intervenção psicopedagógica em caso de criança com neurofibromatose tipo 1

open access: yesRevista Educar +, 2022
Este artigo é um relato de experiência de caso clínico de intervenção psicopedagógica por mediação lúdica com criança acometida de neurofibromatose tipo 1.
Fábia Daniela Schneider Lumertz
doaj   +1 more source

Mandibular trigeminal schwannoma: case report [PDF]

open access: yes, 2001
We report one case of peripheral trigeminal schwannoma originated from the mandibular branch (V3) and located inside the infratemporal and pterygopalatine fossae with slight intracranial extension.
Braga, Fernando de Menezes   +2 more
core   +4 more sources

Síndrome de moyamoya associada a neurofibromatose tipo I em paciente pediátrico [PDF]

open access: yes, 2011
CONTEXT: Neurofibromatosis type 1 (NF-1) is the most prevalent autosomal dominant genetic disorder among humans. Moyamoya disease is a cerebral vasculopathy that is only rarely observed in association with NF-1, particularly in the pediatric age range ...
DARRIGO JÚNIOR, Luiz Guilherme   +5 more
core   +1 more source

Hémothorax spontané: complication rare de la neurofibromatose type 1

open access: yesThe Pan African Medical Journal, 2017
La neurofibromatose de type 1 (NF1) ou maladie de Von Recklinghausen est une maladie héréditaire la plus fréquente des phacomatoses, de transmission autosomique dominante. Ses complications pulmonaires sont rarement décrites dans la littérature.
Soumia Fdil   +2 more
doaj   +1 more source

Atteinte pulmonaire sévère au cours de la neurofibromatose de type 1 [PDF]

open access: yes, 2014
Type 1 neurofibromatosis (NF1) is a hereditary disease inherited as an autosomal dominant. Respiratory involvement is rare. We report the case of a woman suffering from NF1 with mutation of the corresponding gene and with respiratory involvement ...
A. Paris   +7 more
core   +4 more sources

Neurofibromatose tipo 1: relato de um caso clínico

open access: yesRevista Portuguesa de Medicina Geral e Familiar, 2013
Introdução: A neurofibromatose tipo 1 (NF1) é uma doença neurocutânea de hereditariedade autossómica dominante, ocorrendo mutações de novo em cerca de metade dos casos.
Ana Catarina Marques, Fátima Dinis
doaj   +1 more source

Neurofibromatosis: part 2 – clinical management

open access: yesArquivos de Neuro-Psiquiatria, 2015
Part 1 of this guideline addressed the differential diagnosis of the neurofibromatoses (NF): neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SCH). NF shares some features such as the genetic origin of the neural tumors
Pollyanna Barros Batista   +27 more
doaj   +1 more source

Home - About - Disclaimer - Privacy